AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04298788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue dishware
Description: blue dishware is used for plates and bowls
Study NCT02888457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal sampling with a swab
Study NCT04310072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
Study NCT02698891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02698891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Study NCT01609517 — intervention group
Intervention type: DRUG
Intervention: Spinal anesthesia (heavy bupivacaine)
Description: Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
Study NCT03239899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
Study NCT01468376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-02
Description: 14 day dosing
Study NCT01468376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-03
Description: 14 day dosing
Study NCT03087084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Pacing and Impedance Measurement system
Description: Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
Study NCT01468376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-04
Description: 14 day dosing
Study NCT01468376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-05
Description: 14 day dosing
Study NCT00904852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandutinib, bevacizumab, and temozolomide
Description: All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
Study NCT00554736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus L-92
Description: Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
Study NCT02163876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuCNS-SC cells
Description: surgery arm
Study NCT01458210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Administered orally
Study NCT01458210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered subcutaneously
Study NCT04674436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: 6 minute casual walk
Study NCT02452918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Description: Administered intravenously
Study NCT02452918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered as a concomitant medication at a standard dose and dosing schedule
Study NCT04525170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPT treatment
Study NCT04525170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: untreated
Study NCT02729558 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: local SRT
Description: local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
Study NCT00417976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 over 100 minutes every 2 weeks.
Study NCT01468376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLU-06
Description: 14 day dosing
Study NCT03729154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Step
Description: First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
Study NCT00417976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg every 2 weeks.
Study NCT01727128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT03629730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coordination training
Description: The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
Study NCT03629730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordination training
Description: The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
Study NCT03703037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and Doppler ultrasound
Description: Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
Study NCT01486550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (Hydroxyethyl starch 130/0,4)
Description: 7,5 ml/kg in the first hour and then 5 ml/kg minimum
Study NCT01486550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/ml
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study NCT03071848 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This was an observational study.
Study NCT01241435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT01948960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus dose escalation
Description: patients with an AUC below mean will have dose escalation of everolimus based on their AUC
Study NCT03861767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: tablet
Study NCT03861767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
Study NCT01188499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Study NCT00417976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusional 5-Fluorouracil
Description: 2400 mg/m2 over 48 hours every 2 weeks.
Study NCT01985009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FibroScan® examination.
Description: The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
Study NCT04058262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation presential
Description: Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
Study NCT04058262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
Study NCT04058262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation (app)
Description: Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
Study NCT04058262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: round of conversation
Description: The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
Study NCT04973033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: patients enrolled were prescribed tofacitinib 5mg twice a day orally.
Study NCT00909701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOP Booster
Description: 1 serving of 400 ml per study arm
Study NCT00909701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PreOP (Nutricia Clinical Care, Trowbridge, UK)
Description: 1 serving of 400 ml per study arm
Study NCT00817947 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High frequency chest wall oscillation
Description: Airway clearance using high frequency chest wall oscillation ('The Vest')
Study NCT01258972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent with main branch DES
Description: Tryton Side Branch Stent
Study NCT01258972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA
Description: Balloon angioplasty
Study NCT00703755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
Study NCT00703755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
Study NCT00703755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
Study NCT00703755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
Study NCT00703755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
Study NCT00703755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate /Metformin
Description: fenofibrate placebo + metformin 850 mg bid (F0-M1700)
Study NCT00703755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00148733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Study NCT00148733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Study NCT02460757 — intervention group
Intervention type: OTHER
Intervention: Laryngoscopy
Description: Observation of glottic width in different arms
Study NCT02103790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home NIV installation
Study NCT04570657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2
Study NCT04570657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive multiple doses of placebo
Study NCT03689504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard of care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
Study NCT03689504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
Study NCT03689504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based nutrition education
Description: Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
Study NCT02401646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polygoni Multiflori Radix complex extract
Description: Intervention is manufactured by Chun-Ho food
Study NCT02401646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is filled with starch, so does not contain the active ingredient.
Study NCT00817947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency chest wall oscillation
Description: Airway clearance using high frequency chest wall oscillation ('The Vest')
Study NCT03845413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Schedule an appointment to attend tobacco cessation at Basic Health Unit
Study NCT03845413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
Description: 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
Study NCT01917968 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uphold Lightweight Vaginal Support System
Description: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
Study NCT01917968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional native tissue repair
Description: Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
Study NCT01434576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGS1025
Description: 2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
Study NCT01434576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGS1025
Description: 10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
Study NCT01434576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
Study NCT04440449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle App
Description: A mobile app used to assist with lifestyle changes
Study NCT04440449 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle App
Description: A mobile app used to assist with lifestyle changes
Study NCT04440449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Look AHEAD behavior lifestyle intervention
Description: A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
Study NCT04440449 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Abbreviated Look AHEAD behavior lifestyle intervention
Description: An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
Study NCT01351350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules
Study NCT01351350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel intravenous infusion
Study NCT01781988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, gemcitabine , pametrexed
Description: A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression.
Study NCT01209767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis
Description: During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
Study NCT01209767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision
Description: Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
Study NCT01209767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT01351350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab intravenous infusion
Study NCT00400686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
Study NCT03580044 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ATM-AVI
Description: ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
Study NCT03580044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
Study NCT01365754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: fusion
Study NCT01365754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: new
Description: dynamic stabilization
Study NCT00481936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB6-845
Description: Intravenous infusion once weekly for 4 weeks